In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Perkin-Elmer/PerSeptive Biosystems: PE expands its "proteomics" technology portfolio by completing proposed $360 mil. PerSeptive buy, a definitive stock-swap deal for which was announced on Aug. 25 ("The Gray Sheet" Sept. 1, 1997, p. 6). The combination will create a fully integrated technology platform in the field of biomedical research and drug discovery, PE claims...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.